FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128327954> ?p ?o ?g. }

• W2128327954 endingPage "2081" @default.
• W2128327954 startingPage "2073" @default.
• W2128327954 abstract "In our previous studies using combined radioisotopes with chemotherapeutic liposomal drugs (i.e., (111)In-labeled polyethylene glycol (PEG)ylated liposomal vinorelbine) we have reported possible therapeutic efficiency in tumor growth suppression. Nevertheless, the challenge remains as to whether this chemotherapy has a therapeutic effect as good as that of combination therapy. The goal of this study was to investigate the real therapeutic effectiveness of 6 mol% PEG (111)In-vinorelbine liposomes via the elevation of the radiation dosage and reduction in the concentration of chemotherapeutic agents.Murine colon carcinoma cells transfected with dual-reporter genes (CT-26/tk-luc) were xenografted into BALB/c mice. The biodistribution was estimated to determine the drug profile and targeting efficiency of (111)In-vinorelbine liposomes. Bioluminescence imaging and (18)F-FDG small-animal PET were applied to monitor the therapeutic response after drug administration. The survival in vivo was estimated and linked with the toxicologic and histopathologic analyses to determine the preclinical safety and feasibility of the nanomedicine.Effective long-term circulation of radioactivity in the plasma was achieved by 6 mol% PEG (111)In-vinorelbine liposomes, and this dose showed significantly lower uptake in the reticuloendothelial system than that of 0.9 mol% PEG (111)In-vinorelbine liposomes. Selective tumor uptake was represented by cumulative deposition, and the maximum accumulation was at 48 h after injection. The combination therapy exhibited an additive effect for tumor growth suppression as tracked by caliper measurement, bioluminescence imaging, and small-animal PET. Furthermore, an improved survival rate and reduced tissue toxicity were closely correlated with the toxicologic and histopathologic results.The results demonstrated that the use of 6 mol% PEG (111)In-vinorelbine liposomes for passively targeted tumor therapy displayed an additive effect with combined therapy, not only by prolonging the circulation rate because of a reduction in the phagocytic effect of the reticuloendothelial system but also by enhancing tumor uptake. Thus, this preclinical study suggests that 6 mol% PEG (111)In-vinorelbine liposomes have the potential to increase the therapeutic index and reduce the toxicity of the passively nanotargeted chemoradiotherapies." @default.
• W2128327954 created "2016-06-24" @default.
• W2128327954 creator A5012498951 @default.
• W2128327954 creator A5029313920 @default.
• W2128327954 creator A5030467912 @default.
• W2128327954 creator A5043751769 @default.
• W2128327954 creator A5051926057 @default.
• W2128327954 creator A5054687824 @default.
• W2128327954 creator A5061082492 @default.
• W2128327954 creator A5068532210 @default.
• W2128327954 creator A5068775874 @default.
• W2128327954 creator A5091551920 @default.
• W2128327954 date "2009-11-30" @default.
• W2128327954 modified "2023-09-23" @default.
• W2128327954 title "Therapeutic Efficacy Evaluation of ¹¹¹In-Labeled PEGylated Liposomal Vinorelbine in Murine Colon Carcinoma with Multimodalities of Molecular Imaging" @default.
• W2128327954 cites W1918322381 @default.
• W2128327954 cites W1960327677 @default.
• W2128327954 cites W1969790128 @default.
• W2128327954 cites W1973153810 @default.
• W2128327954 cites W1984761779 @default.
• W2128327954 cites W2013470095 @default.
• W2128327954 cites W2023275561 @default.
• W2128327954 cites W2024182029 @default.
• W2128327954 cites W2046635748 @default.
• W2128327954 cites W2048834254 @default.
• W2128327954 cites W2061510929 @default.
• W2128327954 cites W2070825008 @default.
• W2128327954 cites W2071636590 @default.
• W2128327954 cites W2073677617 @default.
• W2128327954 cites W2074544404 @default.
• W2128327954 cites W2078246957 @default.
• W2128327954 cites W2084693381 @default.
• W2128327954 cites W2087597184 @default.
• W2128327954 cites W2108763010 @default.
• W2128327954 cites W2111598262 @default.
• W2128327954 cites W2111764722 @default.
• W2128327954 cites W2115983210 @default.
• W2128327954 cites W2153302882 @default.
• W2128327954 cites W2163409320 @default.
• W2128327954 doi "https://doi.org/10.2967/jnumed.109.063503" @default.
• W2128327954 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19949027" @default.
• W2128327954 hasPublicationYear "2009" @default.
• W2128327954 type Work @default.
• W2128327954 sameAs 2128327954 @default.
• W2128327954 citedByCount "45" @default.
• W2128327954 countsByYear W21283279542012 @default.
• W2128327954 countsByYear W21283279542013 @default.
• W2128327954 countsByYear W21283279542014 @default.
• W2128327954 countsByYear W21283279542015 @default.
• W2128327954 countsByYear W21283279542016 @default.
• W2128327954 countsByYear W21283279542017 @default.
• W2128327954 countsByYear W21283279542018 @default.
• W2128327954 countsByYear W21283279542019 @default.
• W2128327954 countsByYear W21283279542020 @default.
• W2128327954 countsByYear W21283279542022 @default.
• W2128327954 countsByYear W21283279542023 @default.
• W2128327954 crossrefType "journal-article" @default.
• W2128327954 hasAuthorship W2128327954A5012498951 @default.
• W2128327954 hasAuthorship W2128327954A5029313920 @default.
• W2128327954 hasAuthorship W2128327954A5030467912 @default.
• W2128327954 hasAuthorship W2128327954A5043751769 @default.
• W2128327954 hasAuthorship W2128327954A5051926057 @default.
• W2128327954 hasAuthorship W2128327954A5054687824 @default.
• W2128327954 hasAuthorship W2128327954A5061082492 @default.
• W2128327954 hasAuthorship W2128327954A5068532210 @default.
• W2128327954 hasAuthorship W2128327954A5068775874 @default.
• W2128327954 hasAuthorship W2128327954A5091551920 @default.
• W2128327954 hasBestOaLocation W21283279541 @default.
• W2128327954 hasConcept C102652120 @default.
• W2128327954 hasConcept C104317684 @default.
• W2128327954 hasConcept C111335760 @default.
• W2128327954 hasConcept C112705442 @default.
• W2128327954 hasConcept C126322002 @default.
• W2128327954 hasConcept C150903083 @default.
• W2128327954 hasConcept C161997846 @default.
• W2128327954 hasConcept C185154212 @default.
• W2128327954 hasConcept C185592680 @default.
• W2128327954 hasConcept C19831878 @default.
• W2128327954 hasConcept C207001950 @default.
• W2128327954 hasConcept C2776694085 @default.
• W2128327954 hasConcept C2777807558 @default.
• W2128327954 hasConcept C2778239845 @default.
• W2128327954 hasConcept C2780035454 @default.
• W2128327954 hasConcept C2780350996 @default.
• W2128327954 hasConcept C502942594 @default.
• W2128327954 hasConcept C54009773 @default.
• W2128327954 hasConcept C55493867 @default.
• W2128327954 hasConcept C71924100 @default.
• W2128327954 hasConcept C86803240 @default.
• W2128327954 hasConcept C98274493 @default.
• W2128327954 hasConceptScore W2128327954C102652120 @default.
• W2128327954 hasConceptScore W2128327954C104317684 @default.
• W2128327954 hasConceptScore W2128327954C111335760 @default.
• W2128327954 hasConceptScore W2128327954C112705442 @default.
• W2128327954 hasConceptScore W2128327954C126322002 @default.
• W2128327954 hasConceptScore W2128327954C150903083 @default.
• W2128327954 hasConceptScore W2128327954C161997846 @default.
• W2128327954 hasConceptScore W2128327954C185154212 @default.

• next